Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial

Journal of the American College of Surgeons
Ritesh PatilG E Peoples

Abstract

We have treated disease-free breast cancer patients with an HER2/neu-derived peptide, E75, as an adjuvant vaccine. E75 was originally described as HLA-A2-restricted and has been previously tested in this population. Based on computer modeling, E75 is predicted to bind to HLA-A3, and preclinical data support this. We conducted a clinical trial of E75 in HLA-A3(+), A2(-) (A3) patients. Disease-free breast cancer patients were enrolled after standard therapy in phase I/II trials. A3 patients were enrolled in parallel with A2 patients and vaccinated with E75 and granulocyte-macrophage colony-stimulating factor immunoadjuvant. A2(-), A3(-) patients were followed as controls. Toxicities were graded. Immunologic responses were assessed by delayed-type hypersensitivity reactions and E75-specific interferon-gamma enzyme-linked immunosorbent spot assay. Clinical recurrences were documented. Thirteen A3 patients completed the vaccine schedule. Clinicopathologic features were similar between A3, A2, and control patients, except for more HER2/neu-overexpressing tumors in the A2 group and more estrogen-receptor/progesterone-receptor-negative tumors in A2 and A3 groups. Toxicity profiles and postvaccination delayed-type hypersensitivity were ...Continue Reading

Associated Clinical Trials

References

May 1, 1992·The Journal of Experimental Medicine·L A ShermanJ A Biggs
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·R CibottiP Kourilsky
May 15, 1985·International Journal of Cancer. Journal International Du Cancer·R V IaffaioliS Zappacosta
Sep 19, 2003·Cancer Immunology, Immunotherapy : CII·Panagiota A SotiropoulouConstantin N Baxevanis
May 19, 2005·International Journal of Cancer. Journal International Du Cancer·Zahra MadjdLindy G Durrant
Jul 9, 2005·International Journal of Cancer. Journal International Du Cancer·Nicholas F S WatsonLindy G Durrant
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew T HuemanGeorge E Peoples
May 19, 2006·The New England Journal of Medicine·Kathleen I PritchardUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Phil RollandIan Spendlove
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffPatrice K Rehm
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George E PeoplesSathibalan Ponniah
Jun 10, 2008·Cancer Immunology, Immunotherapy : CII·Elizabeth A MittendorfGeorge E Peoples
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jarrod P HolmesGeorge E Peoples

❮ Previous
Next ❯

Citations

Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MilaniG Valabrega
Jan 22, 2011·Pathology Research International·Holly Graves, Brian J Czerniecki
Dec 21, 2012·Expert Review of Anticancer Therapy·Leisha A Emens
Oct 29, 2010·Expert Opinion on Biological Therapy·Kewal K Jain
Jul 26, 2012·Journal of Pharmaceutical Sciences·Lipika ChablaniMartin J D'Souza
Nov 3, 2015·Biotechnology Advances·Lívia de Paula PeresMarcelo José Barbosa Silva
Apr 6, 2016·Future Oncology·Guy T CliftonElizabeth A Mittendorf
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Kue Peng LimSok Ching Cheong
Apr 21, 2012·Journal of Pharmaceutical and Biomedical Analysis·Andrea PenwellLeeladhar Sammatur
Jun 7, 2018·Cancer Biotherapy & Radiopharmaceuticals·Naipeng CuiChuanwei Yang
Sep 11, 2018·Expert Opinion on Investigational Drugs·Enrique Soto-Perez-De-CelisArti Hurria
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
May 29, 2014·Expert Review of Clinical Immunology·Elham MohitMojgan Allahyari
Jan 10, 2020·Archivum Immunologiae Et Therapiae Experimentalis·Atefeh ArabJavad Behravan
Nov 2, 2017·Oncotarget·Leonardo MirandolaMaurizio Chiriva-Internati
Oct 31, 2019·Journal of Hematology & Oncology·E KrasniqiP Vici
Jul 29, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Hatem Soliman
Jul 7, 2018·Seminars in Immunopathology·T TranEric Tartour
Mar 24, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thi TranEric Tartour
Jan 15, 2018·Journal of Proteomics·Dmitri V RozanovPaul T Spellman
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MilaniG Valabrega

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.